NCT03216096View on ClinicalTrials.gov

Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 8, 2017

Primary Completion Date

February 1, 2018

Study Completion Date

February 1, 2018

Conditions
Dry Eye Disease
Interventions
DRUG

Placebo ophthalmic solution and 3% DE-089 ophthalmic solution

Placebo ophthalmic solution; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 2-week run-in period 3% DE-089 ophthalmic solution; ; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 4-week treatment period

Trial Locations (2)

Unknown

Keelung Chang Gung Memorial Hospital, Keelung

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

Santen Pharmaceutical Co., Ltd.

INDUSTRY

NCT03216096 - Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease | Biotech Hunter | Biotech Hunter